Recent Updates
Recently added Catalysts
IMMP

October 2015 CHANGE OF ADDRESS In accordance with Listing Rule 3.14, Prima BioMed Limited (ASX: PRR; NASDAQ: PBMD) advises that effective today, our registered office and principal administrative office is now Level 12,

Tuesday, October 20, 2015 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Listing Rule 3.14, Prima BioMed Limited (ASX: PRR; NASDAQ: PBMD) advises that effective today, our registered office and principal administrative office is now Level 12, 95 Pitt Street, Sydney, NSW, Australia 2000. Our new general telephone number and facsimile number are as set

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Full Press Release Details

Listing Rule 3.14, Prima BioMed Limited (ASX: PRR; NASDAQ: PBMD) advises that effective today, our registered office and principal administrative office is now Level 12, 95 Pitt Street, Sydney, NSW, Australia 2000.
Our new general telephone number and facsimile number are as set out below.
Yours sincerely
Deanne Miller
General Counsel and Company Secretary
Prima BioMed Ltd
Ltd, Level 12, 95 Pitt Street, Sydney, NSW
ShareAdd on Google
Tags: IMMP Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Oct 20, 2015

Biotech snapshot

Lead asset
eftilagimod alfaPhase 3
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) →

Catalyst track record

+76%
best trade around IMMP's most recent catalyst

Peak hindsight return over a 120-day window, across 13 tracked FDA/PDUFA catalysts for IMMP.

See every catalyst's timing & PoA →